- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03178214
Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration
A Single Centre, Open-label, Randomised, Single Dose, Three-period, Crossover Study to Evaluate the Bioavailability of Infacort Administered as Sprinkles With Soft Food and Yoghurt Compared With Direct Administration to the Back of the Tongue in Dexamethasone-suppressed Healthy Adult Male Subjects
This is a single centre, open-label, randomised, single dose, three-period, crossover study to evaluate the bioavailability of Infacort® administered as 'sprinkles' with soft food and yoghurt compared with direct administration to the back of the tongue in dexamethasone-suppressed healthy adult male subjects.
The study will comprise of a pre-study screen, followed by 3 treatment periods and a post-study follow-up.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Merthyr Tydfil, United Kingdom, CF48 4DR
- Simbec Research Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male subjects between 18 and 45 years of age, inclusive (at screening).
- A BMI of 18-30 kg/m2 (inclusive).
- No clinically significant abnormal serum biochemistry, haematology or urine examination values as defined by the Investigator.
- A negative urinary drugs of abuse screen. A positive alcohol test may be repeated at the discretion of the Investigator.
- Negative HIV and Hepatitis B and C results.
- No clinically significant abnormalities in 12-lead ECG as defined by the Investigator.
- No clinically significant deviation outside the normal ranges for blood pressure and heart rate measurements as defined by the Investigator (please refer to appendix 1 for normal ranges).
Subjects (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) and sexual partners must use 2 effective contraception methods during the trial and for 3 months after the last dose, for example:
- Oral contraceptive + condom
- Intra-uterine device (IUD) + condom
- Diaphragm with spermicide + condom
- Subjects must be available to complete all three periods of the study and the follow-up visit.
- Subjects must satisfy a medical examiner about their fitness to participate in the study.
- Subjects must be able to read and understand the informed consent form and must provide written informed consent to participate in the study.
Exclusion Criteria:
- A clinically significant history of gastrointestinal disorder likely to influence drug absorption.
- Receipt of any medication other than paracetamol within the 14 days prior to dosing (including topical steroids, high dose vitamins, dietary supplements or herbal remedies).
- Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
- Receipt of any vaccination within the previous one month.
- Presence of infections (systemic fungal and viral infections, acute bacterial infections).
- Current or previous history of tuberculosis.
- A clinically significant history of previous allergy/sensitivity to hydrocortisone, dexamethasone and/or any of the ingredients contained within the yoghurt or soft food (this includes lactose intolerance).
- Meeting any of the contraindications for dexamethasone, as detailed in the Summary of Product Characteristics (SmPC).
- A clinically significant history of drug or alcohol abuse.
- Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
- Participation in a New Chemical Entity or marketed drug clinical study within the previous 3 months or, five half-lives of study drug, whichever is the longer period. (NB. the three month washout period between trials is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
- Subjects who have consumed more than two units of alcohol per day within seven days prior to the first dose or have consumed any alcohol within the 48-hour period prior to the first dose.
- Donation or receipt of equal to/more than 450 mL of blood within the previous three months.
- Subjects who smoke (or ex-smokers who have smoked within six months prior to first dose. This includes e-cigarette and shisha users).
- Subjects who work shifts (i.e. regularly alternate between days, afternoons and nights).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Infacort - Yoghurt
One single 5mg dose of Infacort will be sprinkled onto 5mL of yoghurt and swallowed within three minutes.
This will be taken with 240mL of water.
|
Immediate-release multiparticulate formulation of hydrocortisone.
|
EXPERIMENTAL: Infacort - Soft Food
One single 5mg dose of Infacort will be sprinkled onto 5mL of soft food (such as applesauce) and swallowed within three minutes.
This will be taken with 240mL of water.
|
Immediate-release multiparticulate formulation of hydrocortisone.
|
ACTIVE_COMPARATOR: Infacort - Dry Granules
One single 5mg dose of Infacort will be administered as dry granules to the back of the tongue and swallowed.
This will be taken with 240mL of water.
|
Immediate-release multiparticulate formulation of hydrocortisone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve (AUC) (0-t) of Infacort administered with yoghurt and soft food compared to dry granules administered to the back of the tongue
Time Frame: 12 hours post-IMP administration
|
The pharmacokinetic parameter AUC0-inf of Infacort® administered as sprinkles with yoghurt and soft food compared to Infacort® administered as dry granules to the back of the tongue.
|
12 hours post-IMP administration
|
Area under the curve (AUC) (0-infinity) of Infacort administered with yoghurt and soft food compared to dry granules administered to the back of the tongue
Time Frame: 12 hours post-IMP administration
|
The pharmacokinetic parameter AUC0-inf of Infacort® administered as sprinkles with yoghurt and soft food compared to Infacort® administered as dry granules to the back of the tongue.
|
12 hours post-IMP administration
|
Cmax of Infacort administered with yoghurt and soft food compared to dry granules administered to the back of the tongue.
Time Frame: Up to 12 hours post-IMP adminstration
|
The pharmacokinetic parameter Cmax of Infacort® administered as sprinkles with yoghurt and soft food compared to Infacort® administered as dry granules to the back of the tongue.
|
Up to 12 hours post-IMP adminstration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax of Infacort® administered as sprinkles with yoghurt and soft food compared to Infacort® administered as dry granules to the back of the tongue.
Time Frame: Up to 12 hours post-IMP administration
|
Tmax of Infacort® administered as sprinkles with yoghurt and soft food compared to Infacort® administered as dry granules to the back of the tongue.
|
Up to 12 hours post-IMP administration
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Infacort 006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adrenal Insufficiency
-
University Hospital TuebingenCompletedAdrenal InsufficiencyGermany
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingGlucocorticoid-induced Adrenal InsufficiencyFrance
-
Tobias ElseCorcept TherapeuticsTerminatedMifepristone | Central Adrenal InsufficiencyUnited States
-
Assistance Publique Hopitaux De MarseilleTerminatedAdrenocortical InsufficiencyFrance
-
Diurnal LimitedActive, not recruitingPrimary Adrenal InsufficiencyGermany, United Kingdom
-
University of Roma La SapienzaCompletedSecondary Adrenal Insufficiency | Primary Adrenal InsufficiencyItaly
-
Chronic Obstructive Pulmonary Disease Trial Network...Rigshospitalet, DenmarkCompleted
-
Bruno AllolioCompletedPrimary Adrenal InsufficiencyGermany
-
University of BergenKarolinska Institutet; Charite University, Berlin, GermanyActive, not recruitingPrimary Adrenal InsufficiencyNorway, Sweden, Germany
-
University Medical Center GroningenCompletedAdrenal InsufficiencyNetherlands
Clinical Trials on Infacort
-
Diurnal LimitedSimbec ResearchCompleted
-
Diurnal LimitedTreatment of Adrenal Insufficiency in Neonates consortium (TAIN)Completed
-
Diurnal LimitedCompleted
-
Diurnal LimitedSimbec Research; Brush Clinical Research Ltd.; Voet Consulting; Medical Matters... and other collaboratorsCompletedAdrenal InsufficiencyUnited Kingdom
-
Diurnal LimitedSimbec ResearchCompleted